This cluster randomized trial compares the effect of a nurse home visitation program augmented by an intimate partner violence (IPV) intervention vs nurse home visitation alone on quality of life 24 months after delivery among first-time mothers experiencing social and economic disadvantage.
This national survey study uses National Health and Nutrition Examination Survey (NHANES) data to describe trends in sedentary behaviors of the adolescent and adult US population, including watching television or videos for 2 or more hours per day, computer use 1 or more hour per day, and total sitting time.
This study uses national health statistics data to evaluate associations between state Medicaid expansion in 2014-2016 and changes in rates of low birth weight and preterm birth, both overall and by race/ethnicity.
This study uses Medicaid drug utilization data to describe reimbursement and market share of long-acting insulins before and after approval of new insulin products and to estimate savings associated with a “biosimilar” for insulin glargine approved in 2015.
This study characterizes the prevalence and content of US state statutes governing treatment decisions for decisionally incapacitated pregnant women.
This extension of the CONSORT 2010 Statement, a guideline and checklist for reporting parallel group randomized trials, provides updates for the reporting of multi-arm trials to assist evaluations of rigor and reproducibility and enhance understanding of the methodology of trials with more than 2 comparison arms.
This Viewpoint proposes ways states can control the costs of expensive drugs produced by single manufacturers, including importation from other countries, international benchmark pricing, and statewide upper payment limits.
In this Viewpoint, Peter Bach and colleague Stacie Dusetzina question the assumption underlying a 2019 proposed federal rule change to eliminate drug manufacturer rebates to pharmacy benefit managers (PBMs) as a way to decrease prescription drug prices, and they propose more extensive restructuring, including a cap on out-of-pocket spending for Medicare Part D beneficiaries, to better control drug costs and save patients money.
This Viewpoint reviews proposed changes to regulations governing Canada’s Patented Medicine Process Review Board, a group mandated by Canada’s government to ensure manufacturers do not charge excessive drug prices, including use of cost-utility analyses to define excessive pricing, revision of reference country comparisons, and reducing regulatory burdens for generic drugs.
This Viewpoint discusses the costs of emerging therapies for conditions prevalent in the US Baby Boomer population now entering old age and proposes principles to ensure the value and accessibility of new expensive drugs including cost-effectiveness (CE) assessments, price-benefit alignment, and incorporation of CE data into clinical practice guidelines.
In this narrative medicine essay a neurointensivist discusses her evolving understanding of her personal and professional responses to patient deaths, the pressures physicians face not to grieve, and the importance of attending patients’ funerals for bringing closure to relationships with patient families and easing feelings of guilt, sadness, isolation, and denial.
This JAMA Insights Clinical Update reviews the diagnosis and treatment options for small kidney tumors including active surveillance, biopsy, radical nephrectomy, and nephron-sparing treatments (partial nephrectomy and percutaneous ablation).
A 53-year-old man with a history of pseudogout and receiving immunosuppressives after renal transplant had 2 weeks of stiff neck, headache, and fevers and 3 days of right knee pain and swelling with nuchal rigidity, a positive Kernig sign, no focal neurologic deficits, and a right knee effusion on examination. Blood and CSF cultures were negative, WBC count was high normal, and cervical MRI showed degenerative changes with periodontoid calcifications and reactive marrow. What is the diagnosis and what would you do next?
This Medical News article is an interview with Yasmin Mossavar-Rahmani, PhD, RD, who studied the association of artificially sweetened beverages with cardiovascular disease and mortality in women.
This Medical News article discusses prenatal and peripubertal exposures to phthalates, parabens, and phenols and associations with puberty timing.
This JAMA Patient Page describes the symptoms, diagnosis, and treatment of croup in children.
Create a personal account or sign in to: